Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS

Jonathan I. Silverberg, Gil Yosipovitch, Eric L. Simpson, Brian S. Kim, Jashin J. Wu, Laurent Eckert, Isabelle Guillemin, Zhen Chen, Marius Ardeleanu, Ashish Bansal, Mandeep Kaur, Ana B. Rossi, Neil M.H. Graham, Naimish Patel, Abhijit Gadkari

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Background: Pruritus (itch) is a cardinal symptom in atopic dermatitis (AD). Objective: To evaluate the timing and effect of dupilumab on itch. Methods: Analysis of data from 1505 patients with moderate to severe AD included in 4 randomized controlled studies, treated for up to 52 weeks. Adults received dupilumab 300 mg every 2 weeks or placebo monotherapy (SOLO 1: NCT02277743; SOLO 2: NCT02277769), with concomitant topical corticosteroids (CHRONOS: NCT02260986); adolescents (≥12 to <18 y) were treated with dupilumab monotherapy every 2 weeks (200 mg for baseline weight of <60 kg; 300 mg for baseline weight of ≥60 kg) or placebo (AD ADOL: NCT03054428). Results: Dupilumab showed significant rapid improvements from baseline in daily Peak Pruritus Numerical Rating Scale scores versus placebo, by day 2 in adults and day 5 in adolescents. At treatment end, dupilumab vs placebo/control had greater least-squares mean percent change from baseline in the weekly average of Peak Pruritus Numerical Rating Scale scores: SOLO −47.5% vs −20.5%; AD-ADOL −47.9% vs −19.0%; CHRONOS −57.3% vs −30.9% (P < .0001 for all). Limitations: Short duration of monotherapy trials (16 weeks). Conclusion: Across 4 randomized trials, dupilumab treatment showed rapid and sustained improvements in the magnitude of itch, starting with first dose; responses progressively increased and were sustained through to the end of treatment, up to 1 year.

Original languageEnglish (US)
Pages (from-to)1328-1336
Number of pages9
JournalJournal of the American Academy of Dermatology
Volume82
Issue number6
DOIs
StatePublished - Jun 2020
Externally publishedYes

Keywords

  • adolescents
  • adults
  • atopic dermatitis
  • CHRONOS
  • dupilumab
  • itch
  • LIBERTY
  • SOLO

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS'. Together they form a unique fingerprint.

  • Cite this

    Silverberg, J. I., Yosipovitch, G., Simpson, E. L., Kim, B. S., Wu, J. J., Eckert, L., Guillemin, I., Chen, Z., Ardeleanu, M., Bansal, A., Kaur, M., Rossi, A. B., Graham, N. M. H., Patel, N., & Gadkari, A. (2020). Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. Journal of the American Academy of Dermatology, 82(6), 1328-1336. https://doi.org/10.1016/j.jaad.2020.02.060